Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NCT05887258Phase 3Completed
Phase 3, randomised trial of dexmedetomidine, Lidocaine Hydrochloride Injection, without epinephrine, magnesium sulfate and ketamine in Colorectal disease (2 arms). Primary endpoint: Postoperative pain control at 3 days. Started May 2022; status: completed.
Beyond the preview
Study design, results and competitive context are available in the Gosset platform where reported.
Available in the Gosset platform where reported.
Available in the Gosset platform where reported.
See how Gosset can support your research on NCT05887258.